BioPharma Resources

Drug Trial Radar · NCT06830395

Study of CM313 in Subject With IgA Nephropathy

A Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With Primary IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Mar 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK) characteristics, Pharmacokinetics(PD) effects, and immunogenicity.

Conditions

  • IgA Nephropathy

Interventions

  • CM313Biological

    CM313(SC) injection

  • PlaceboDrug

    Matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs)Time frame: Up to 108 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.